Table 2. Published studies of CP-EBUS and RP-EBUS facilitated FM placement.
Author and year | Patients (number) | Location | Fiducial | MIG (Y/N) | MC rates (%) | Equipment |
---|---|---|---|---|---|---|
Anantham 2007 | 8 | P | Gold seeds | Y | 0 | SuperD/Bronchus/CyberKnife |
Schroeder 2010 | 52 | P | Gold markers; platinum coils | N | 5.8% | SuperD/CyberKnife |
Harley 2010 | 43 | C/P | Gold markers | Y | 2.3% | SuperD/CP-EBUS/CyberKnife |
Roman 2012 | 6 | C/P | Gold visicoil | N | N | SuperD/CP-EBUS |
Hagmeyer 2014 | 6 | P | Gold markers | Y | 0 | SuperD/CyberKnife |
Nabavizadeh 2014 | 31 | P | Platinum coils | N (<2%) | 3.2% | SuperD/RP-EBUS/Novalis SBRT |
Steinfort 2015 | 15 | P | Gold visicoil | Y | 0 | SuperD/RPUS |
Belanger 2016 | 5 | C | Gold (NOS) | N | 0 | CP-EBUS/CyberKnife |
Casutt 2017 | 1 | C | Gold visicoil | N | 0 | CP-EBUS/CyberKnife |
Chambers 2017 | 1 | C | Microembolization coil (cook) | N | 0 | CP-EBUS/IMRT |
Khandhar 2017 | 210 | P | Unknown (pooled data) | Y | 5.7% | ENB (NOS) |
CP-EBUS, convex probe endobronchial ultrasound; RP-EBUS, radial probe endobronchial ultrasound; FM, fiducial marker; P, peripheral; C, central; MC, major complication; MIG, migration; NOS, not otherwise specified; SuperD, SuperDimension; SBRT, stereotactic body radiation therapy; IMRT, intensity modulated radiation therapy; ENB, electromagnetic navigation bronchoscopy; Y, yes; N, no.